Hodgkin’s Lymphoma Market

SKU: DMPH2084 | Last Updated On: Sep 20 2022 | Available Formats

>Hodgkin’s Lymphoma Market Expected to reach at a high CAGR 12.8% by 2029:

Hodgkin’s Lymphoma Market is segmented By Therapy (Targeted Therapy, Chemotherapy, Immunotherapy, Others), By Type (Nodular sclerosis Hodgkin lymphoma, Mixed cellularity Hodgkin lymphoma, Lymphocyte-rich Hodgkin lymphoma, Lymphocyte-depleted Hodgkin lymphoma), By Distribution channel (Hospitals, Clinics, Cancer centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

Hodgkin’s Lymphoma Market is expected to grow at a high CAGR 12.8% during the forecasting period (2022-2029). Hodgkin's Lymphoma is a lymphoid malignancy of B-cell origin classified into nodular lymphocyte-predominant Hodgkin's Lymphoma (NLPHL) and classical Hodgkin's Lymphoma (cHL). Hodgkin's Lymphoma accounts for 15% of all cancers in young adults globally, out of which cHL accounts for 95% of all HL's. Hodgkin lymphoma is diagnosed most commonly in people in their late 20s or early 30s.

Hodgkin’s Lymphoma Market Dynamics

The major driving forces are rising incidence and mortality rates, the high cure rates, and the extended survival of many people with Hodgkin's Lymphoma.

The rising incidence of Hodgkin's Lymphoma is one of the dominating factors propelling the global Hodgkin's lymphoma market. National Cancer Institute reported that in 2019, it is estimated that there will be 8,110 new cases of Hodgkin lymphoma, and an estimated 1,000 people will die of this disease. Thus, growing incidences of Hodgkin's lymphoma are boosting the Hodgkin's Lymphoma market.

The extended survival of people with Hodgkin's Lymphoma is expected to grow significantly during the forecast period. Immunotherapy is expected to show prolonged survival of the patients. This is owing to the US FDA approvals of certain immunotherapeutic drugs like Seattle genetics’s Brentuximab vedotin (Adcetris) in 2018 for the Hodgkin lymphoma treatment.

However, the high cost of chemotherapy and the onset of adverse effects of the treatment are expected to hamper the market. For instance, adverse effects like cardiovascular disease and second malignancies such as acute leukemia, lymphoma, and solid tumors are likely to occur.

Hodgkin’s Lymphoma Market Segmentation

Hodgkin Lymphoma Market can be segmented by therapy as chemotherapy, targeted therapy, immunotherapy, etc.

By therapy, targeted therapy is expected to grow at a high rate over the period of forecast. The drugs will stop the growth and spread of cancer cells and limit harm to normal cells. This is owing to the increased number of US FDA approvals of certain monoclonal antibodies in recent years like Seattle genetics’s Rituximab (Rituxan) and checkpoint inhibitors like Merck’s pembrolizumab (Keytruda) in 2018 for the Hodgkin lymphoma treatment.

Immunotherapy is expected to grow at a significant rate over the period of forecast, owing to increased approvals, increasing research and development activities. Immunotherapy drugs can be used as a first-line treatment for Hodgkin lymphoma, or they can be used in combination with other treatments, like chemotherapy. In December 2018, the multicenter clinical trial, led by Catherine Diefenbach, MD, at NYU School of Medicine and its Perlmutter Cancer Center, found that combination immunotherapy (ipilimumab (Yervoy), nivolumab (Opdivo), and brentuximab vedotin (Adcentris)) showed high activity against recurrent Hodgkin lymphoma.

Chemotherapy is expected to account for the significant market share over the period of forecast, which includes ABVD and BEACOPP regimens due to the increased survival rates and high cure rates of people with Hodgkin's Lymphoma.

By type, the market is segmented as nodular sclerosis Hodgkin lymphoma or NSCHL, mixed cellularity Hodgkin lymphoma or MCCHL, lymphocyte-rich Hodgkin lymphoma, lymphocyte-depleted Hodgkin lymphoma. Among these, nodular sclerosis is expected to share a significant market share.  The American Cancer Society states that it is a common type of Hodgkin disease in developed countries. It accounts for  7 out of 10 cases. Leukemia & Lymphoma Society said that it accounts for 70 % of classical Hodgkin lymphoma cases.

The global Hodgkin’s lymphoma market is segmented into hospitals, clinics, cancer centers, and others by distribution channel. Among these, the hospital segment is expected to grow at a significant rate over the period of forecast. This is owing to the increase in incidences of Hodgkin’s lymphoma cases leading to increased demand for the imaging tests like PET/CT scans. PET/CT scans are commonly used to help the doctors stage Hodgkin’s lymphoma and decide how much treatment should be given. Doctors are even looking at whether PET/CT scans done during the treatment can help them decide if more or less treatment is required.

Hodgkin’s Lymphoma Market



Market CAGR


Segments Covered

By Therapy, By Type, By Distribution channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Hodgkin’s Lymphoma Market Geographical Analysis

The Hodgkin lymphoma market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America dominated the global Hodgkin lymphoma market. This is due to the increasing incidence, rising prevalence, and mortality rate of Hodgkin's Lymphoma region reimbursement schemes.  The American Cancer Society, in 2016, reported that Hodgkin lymphoma affected around 5000 men and 3700 women in the US. Also, about 620 men and 430 women died due to Hodgkin lymphoma treatment.  Thus, the increasing incidence of HL has boosted North America's share in the global Hodgkin's lymphoma market.

An increased number of approvals is expected to drive the market. For instance, in 2018, Seattle Genetics, Inc. received the Health Canada approval for supplemental New Drug Submission that expanded the use of Adcetris (brentuximab vedotin) in combination with AVD (Adriamycin, vinblastine, and dacarbazine) chemotherapy in the patients with previously untreated Stage IV Hodgkin lymphoma.

Increased research and development activities in the region are expected to boost the market. For instance, in December 2016, Ohio State University Comprehensive Cancer Center and National Cancer Institute (NCI) performed a clinical trial of Ibrutinib in Combination with Nivolumab in patients suffering from classical Hodgkin’s Lymphoma in the US to study its efficacy. Ibrutinib may block the cancer cell growth by blocking the enzymes responsible for growth, and Nivolumab may prevent cancer cells by targeting different cells. Currently, it's in the second phase of clinical trials. The study involves 17 participants and is estimated to be completed by 2020.

However, over the forecast period (2020-2027), the Asia-Pacific is expected to dominate the Global Hodgkin's Lymphoma market. The rising incidence and high mortality rates of Lymphoma have surged the market's growth in the region. According to the leukemia Foundation, in 2017, around 11923 new cases have been reported in Australia.

The presence of research and development activities in the region is expected to boost the market. For instance, in September 2017, the Chinese PLA General Hospital, a Chinese government organization, commenced a clinical trial of Decitabine combined with SHR – 1210. SHR – 1210 is a monoclonal antibody, while Decitabine is an investigational drug capable of boosting antigen expression. The clinical study is for analyzing the safety and efficacy of the drugs. Currently, it is in phase 3 of clinical trials and is anticipated to be launched by January 2022.

Hodgkin’s Lymphoma Market Competitive Landscape

The market is moderately concentrated, with a limited number of key players operating in the global Hodgkin lymphoma market. Seattle Genetics, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, Merck & Co., Inc. F Hoffmann-La Roche, Actinium Pharmaceuticals, Aeterna Zentaris Inc., Affimed Therapeutics Ag, Hospira Inc., and Incyte Corporation are the vendors in the market.

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of Hodgkin’s lymphoma market globally. For instance,

On March 14, 2017, The US FDA granted approval to pembrolizumab (Keytruda) of Merck and Co., Inc. for treating adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or the patients who relapsed after three or more prior lines of therapy.

On May 17, 2016, The US FDA approved nivolumab (Opdivo), marketed by Bristol-Myers Squibb, to treat classical Hodgkin lymphoma patients who have relapsed or progressed after an autotransplant and brentuximab vedotin.

Frequently Asked Questions

What is the Projected CAGR value of the Hodgkin’s Lymphoma Market?

Hodgkin’s Lymphoma Market is expected to grow at a CAGR of 2.8% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Hodgkin’s Lymphoma Market during 2022-2029

Which is the fastest growing region in the Hodgkin’s Lymphoma Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

T-cell-lymphoma Market

Mantle Cell Lymphoma Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!